Abstract

CMMI currently maintains an active Histology Laboratory that has provided various histologic staining imtnunoassayprocedures as a service for in-house investigators. This Core Facility will be responsible for tissue procurement,preparation, sectioning, and the performance of immunoenzyme and immunofluorescent assays, microautoradiography,and specialized histochemical procedures. Examination of stained specimens can be carried out by light microscopy,fluorescent microscopy or video densitometer. For the purposes of this grant proposal Dr. Gold, (Core Leader) willreview all slides. Additional assistance in the review of stained slides is available from our collaborators in this ProgramProject, Drs. Ely and Knowles from NY Hospital (NYC, NY). A majority of the specimens for histology services willbe provided by members of the Program Project, either from experimental animal and cell culture studies or clinicalpathology material to be obtained from Drs. Ely and Knowles of the NY Hospital (NYC, NY). As a yearly average weexpect 1250 specimens a year for histology services.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA103985-04
Application #
7728855
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-01
Project End
2009-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
4
Fiscal Year
2008
Total Cost
$65,832
Indirect Cost

  Institution

Name
Center for Molecular Medicine/Immunology
Department
Type
DUNS #
118870583
City
Morris Plains
State
NJ
Country
United States
Zip Code
07950

  Publications

Smith, Mitchell R; Jin, Fang; Joshi, Indira (2014) Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-?B dependent human transformed follicular lymphoma cell line. Br J Haematol 165:151-3
Binsky-Ehrenreich, I; Marom, A; Sobotta, M C et al. (2014) CD84 is a survival receptor for CLL cells. Oncogene 33:1006-16
Chen, X; Chang, C-H; Stein, R et al. (2012) The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplant 47:967-80
Alinari, Lapo; Yu, Bo; Christian, Beth A et al. (2011) Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 117:4530-41
Brem, Elizabeth A; Thudium, Karen; Khubchandani, Sapna et al. (2011) Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol 153:599-611
Sharkey, Robert M; Goldenberg, David M (2011) Cancer radioimmunotherapy. Immunotherapy 3:349-70
Stein, Rhona; Balkman, Cheryl; Chen, Susan et al. (2011) Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leuk Lymphoma 52:273-84
Rossi, Edmund A; Rossi, Diane L; Cardillo, Thomas M et al. (2011) Preclinical studies on targeted delivery of multiple IFN?2b to HLA-DR in diverse hematologic cancers. Blood 118:1877-84
Olejniczak, Scott H; Blickwedehl, Jennifer; Belicha-Villanueva, Alan et al. (2010) Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 116:5605-14
Gupta, Pankaj; Goldenberg, David M; Rossi, Edmund A et al. (2010) Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 116:3258-67

Showing the most recent 10 out of 43 publications